Anti-cervical cancer effects of Compound Yangshe granule through the PI3K/AKT pathway based on network pharmacology

颗粒(地质) 药物数据库 小桶 药理学 体内 体外 医学 传统医学 生物 基因 药品 转录组 基因表达 生物化学 遗传学 古生物学
作者
Chao Ma,Yongwei Gu,Chang Liu,Xiaomeng Tang,Jianchao Yu,Dan Li,Jiyong Liu
出处
期刊:Journal of Ethnopharmacology [Elsevier]
卷期号:301: 115820-115820 被引量:18
标识
DOI:10.1016/j.jep.2022.115820
摘要

Compound Yangshe granule is a characteristic Chinese preparation against cervical cancer used at Fudan University Shanghai Cancer Center, and it consists of Hedyotis Diffusae Herba, Solani Lyrati Herba, Rubiae Radix et Rhizoma, Echinopsis Radix, Angelicae Sinensis Radix, Codonopsis Radix and Atractylodis Macrocephalae Rhizoma.The objective of the current study was to investigate the preclinical efficacy of compound Yangshe granule against cervical cancer and elucidate the underlying mechanisms.Antitumor effect of the preparation was investigated in U14 cells in vitro and subcutaneous xenograft mice in vivo. The underlying mechanisms were investigated by through network pharmacological analysis and identified by in vitro study. The components of compound Yangshe granule were collected from the Traditional Chinese Medicine Systems Pharmacology database, and the corresponding targets were predicted by the SwissTargetPrediction database. The targets involved in cervical cancer were collected from the GeneCards, Online Mendelian Inheritance in Man and DrugBank databases. A protein‒protein interaction network was constructed by using the String platform. The drug-disease-target network was plotted by Cytoscape software. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed to investigate hub targets.After treatment with 0.5-10 mg/mL compound Yangshe granule, the survival rates of U14 cells gradually declined to 53.32% for 24 h, 23.62% for 48 h, and 12.81% for 72 h. The apoptosis rates of U14 cells gradually increased to 15.52% for 24 h, 23.87% for 48 h, and 65.01% for 72 h after treatment with 2-10 mg/mL compound Yangshe granule. After oral administration of compound Yangshe granule by xenograft mice, the tumor inhibition rates reached 52.27%, 74.62%, and 82.70% in the low, middle, and high dose groups, respectively. According to the network pharmacological analysis, quercetin, luteolin and naringenin were the most bioactive ingredients of the preparation. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that compound Yangshe granule may combat cervical cancer through the PI3K/AKT pathway.In summary, network pharmacology combined with biological experiments demonstrated that the main bioactive components including quercetin, luteolin and naringenin could inhibit the tumor growth by regulating the PI3K/AKT pathway and Bcl-2 family. Thus, compound Yangshe granule may be a promising adjuvant therapy for cervical cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
终成发布了新的文献求助50
1秒前
小余同学发布了新的文献求助10
1秒前
lalala完成签到,获得积分10
2秒前
2秒前
小青椒应助FIN采纳,获得50
3秒前
4秒前
qian完成签到 ,获得积分10
4秒前
6秒前
7秒前
8秒前
foxuan完成签到,获得积分10
11秒前
临河盗龙发布了新的文献求助10
11秒前
12秒前
自觉紫安完成签到,获得积分10
12秒前
14秒前
不吃香菜发布了新的文献求助10
14秒前
考博圣体完成签到,获得积分10
15秒前
白云苍狗发布了新的文献求助10
17秒前
笨笨的元风完成签到 ,获得积分10
18秒前
19秒前
20秒前
21秒前
凌奕添完成签到 ,获得积分10
22秒前
考博圣体发布了新的文献求助10
22秒前
23秒前
pyb完成签到 ,获得积分10
24秒前
24秒前
Jasper应助Zenghaw采纳,获得10
24秒前
酷波er应助哎哟可爱采纳,获得10
26秒前
26秒前
26秒前
生动依凝发布了新的文献求助10
26秒前
26秒前
善学以致用应助追寻电脑采纳,获得10
26秒前
27秒前
小余同学发布了新的文献求助10
28秒前
马小燕完成签到,获得积分10
28秒前
礼礼完成签到 ,获得积分10
28秒前
mm发布了新的文献求助10
30秒前
情怀应助怡然静竹采纳,获得10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Fermented Coffee Market 2000
微纳米加工技术及其应用 500
Constitutional and Administrative Law 500
PARLOC2001: The update of loss containment data for offshore pipelines 500
Critical Thinking: Tools for Taking Charge of Your Learning and Your Life 4th Edition 500
Vertebrate Palaeontology, 5th Edition 420
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5287984
求助须知:如何正确求助?哪些是违规求助? 4440026
关于积分的说明 13823687
捐赠科研通 4322271
什么是DOI,文献DOI怎么找? 2372462
邀请新用户注册赠送积分活动 1367928
关于科研通互助平台的介绍 1331548